From the FDA Drug Label
The safety and pharmacokinetic properties of ivermectin were further assessed in a multiple-dose clinical pharmacokinetic study involving healthy volunteers. In general, treatment of an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
The potential effects of a 3-day course of ivermectin in a healthy 66-year-old are not directly stated in the label. Caution is advised when treating elderly patients due to the potential for decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy. However, the label does not provide specific information on the effects of a 3-day course of ivermectin in a healthy 66-year-old. 1 1
From the Research
Potential Effects of Ivermectin
There are no research papers to assist in answering this question, as none of the provided studies mention the use of ivermectin in a healthy 66-year-old.
Relevant Information
- The provided studies discuss various medical conditions and treatments, but none of them involve the use of ivermectin 2, 3, 4, 5, 6.
- The studies cover a range of topics, including infections, surgical site infections, and rare medical conditions, but do not provide information on the effects of ivermectin in a healthy 66-year-old.
- Some studies mention the use of antibiotics and other medications, but ivermectin is not mentioned 2, 3, 4, 5, 6.
Key Points
- No information is available on the potential effects of a 3-day course of ivermectin in a healthy 66-year-old.
- The provided studies do not discuss the use of ivermectin in this context.
- Further research would be needed to determine the potential effects of ivermectin in a healthy 66-year-old 2, 3, 4, 5, 6.